US2018036429A1PendingUtilityA1

Chimeric vsv-g proteins as nucleic acid transfer vehicles

Assignee: SERENDIPITY BIOTECH INCPriority: Apr 25, 2014Filed: Oct 23, 2017Published: Feb 8, 2018

Est. expiryApr 25, 2034(~7.7 yrs left)· nominal 20-yr term from priority

Inventors:Sujata Acharjee

C07K 14/005C07K 2319/80C07K 14/4722C07K 14/435C07K 2319/01A61K 48/0008C07K 2319/85C12N 9/22C12N 2760/20222C12N 15/87

PatentIndex Score

Cited by

References

Claims

Abstract

The design and generation of a number of chimeric VSV-G (or VSV-G variants) proteins are used as transfer vehicles to enhance delivery of nucleic acids like plasmid DNA, single and double stranded DNA and RNA, and antisense oligonucleotides into human and animal cells. These chimeric VSV-G protein-nucleic acid transfer vehicles have widespread applications to deliver nucleic acids for exon skipping and gene delivery for gene replacement in human and animals.

Claims

exact text as granted — not AI-modified

What is claimed is: 
     
         1 . A chimeric protein comprising VSV-G and a nucleic acid binding protein. 
     
     
         2 . The chimeric protein according to  claim 1 , wherein the nucleic acid binding protein is a histone. 
     
     
         3 . The chimeric protein according to  claim 2 , wherein the histone is selected from the group consisting of: H2A, H2B, H3, and H4. 
     
     
         4 . The chimeric protein according to  claim 2 , wherein the histone is tagged with VSV-G at the C-terminus. 
     
     
         5 . The chimeric protein according to  claim 2 , wherein the histone is tagged with VSV-G at the N-terminus. 
     
     
         6 . The chimeric protein according to  claim 4 , wherein the chimeric protein comprises SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7, or SEQ. ID NO.: 8, and pharmacologically acceptable equivalents thereof. 
     
     
         7 . The chimeric protein according to  claim 5 , wherein the chimeric protein comprises SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.: 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, or SEQ. ID NO.: 22, and pharmacologically acceptable equivalents thereof. 
     
     
         8 . The chimeric protein according to  claim 4 , wherein the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7, or SEQ. ID NO.: 8. 
     
     
         9 . The chimeric protein according to  claim 5 , wherein the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.:
 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, or SEQ. ID NO.: 22.   
     
     
         10 . The chimeric protein according to  claim 1 , wherein the nucleic acid binding protein is SSBP-1. 
     
     
         11 . The chimeric protein according to  claim 10 , wherein SSBP-1 is tagged with VSV-G at the C-terminus. 
     
     
         12 . The chimeric protein according to  claim 10 , wherein SSBP-1 is tagged with VSV-G at the N-terminus. 
     
     
         13 . The chimeric protein according to  claim 11 , wherein the chimeric protein comprises SEQ. ID NO.: 9 or SEQ. ID NO.: 10, and pharmacologically acceptable equivalents thereof. 
     
     
         14 . The chimeric protein according to  claim 12 , wherein the chimeric protein comprises SEQ. ID NO.: 23 or SEQ. ID NO.: 24, and pharmacologically acceptable equivalents thereof. 
     
     
         15 . The chimeric protein according to  claim 11 , wherein the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 9 or SEQ. ID NO.: 10. 
     
     
         16 . The chimeric protein according to  claim 12 , wherein the chimeric protein includes a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ. ID NO.: 23 or SEQ. ID NO.: 24. 
     
     
         17 . The chimeric protein according to  claim 1 , wherein the nucleic acid binding protein is RNase III. 
     
     
         18 . The chimeric protein according to  claim 17 , wherein RNase III is tagged with VSV-G at the C-terminus. 
     
     
         19 . The chimeric protein according to  claim 17 , wherein RNase III is tagged with VSV-G at the N-terminus. 
     
     
         20 . The chimeric protein according to  claim 18 , wherein the chimeric protein comprises SEQ. ID NO.: 11, SEQ. ID NO.: 12, or SEQ. ID NO.: 13, and pharmacologically acceptable equivalents thereof.

Join the waitlist — get patent alerts

Track US2018036429A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.